Engineered recombinant antibodies for all
Absolute Antibody has the vision to make recombinant antibody technology accessible to all. They are specialized in antibody sequencing, engineering and recombinant expression, producing an ever-increasing number of engineered recombinant antibodies at their ISO-certified antibody manufacturing facility. Absolute Antibody offers recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats.
Advantages and added values of recombinant antibodies
- Ensured batch-to-batch reproducibility
- High purity, low endotoxin
- Truly defined – No variations, no contamination, no genetic drift, noaccidental loss
- Animal-free manufacturing
- Possibility of endless reproduction
- Possibility to engineer new formats
- Switching of species, isotypes / subtypes
- Chimerization
- Humanization
- Antibody fragments
- Bi- and tri-specifics
- Fc Silent™ versions etc.
Non-IgG isotypes
In addition to all IgG subtypes, Absolute Antibody offers antibodies in the following isotypes: IgM, IgA, IgE, IgD and IgY.
Chimeric Antibodies
Absolute Antibody offers an antibody chimerization service for human, mouse, rat, rabbit and hamster IgG with other species and isotypes available on request.
Antibody fragments
Absolute Antibody converts any antibody into a fragment, including single chain Fv (scFv), Fab or Fab2 formats. Ideal full-length alternative in certain situations!
Fc-Silent versions
Fc Silent™ is a Fc domain developed at Absolute Antibody with abrogated binding of Fc receptors, abolishing antibody directed cytotoxicity effector function.
VivopureX™ antibodies - Ideal for in vivo research
VivopureX™ antibodies are recombinant mouse antibodies ideal for in vivo research in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. These species-matched chimeric antibodies consist of a clone’s original antigen-binding variable domain with a mouse constant domain.
- No induction of neutralizing antibodies in the host
- Increased potency
- Suits the most popular applications
- Batch-to-batch reproducibility, high purity and low endotoxins
Supporting data for VivopureX™ antibodies
Mean tumor sizes in animals treated with PD-1 mouse IgG2a Fc Silent™ antibody based on clone RMP1-14 (Ab00813-2.3) are significantly smaller than in animals treated with the traditional rat IgG2a antibody (Ab00813-7.1)
VivopureX™ antibodies
Antibody Name [Clone] | Engineered Format | Top Application |
||
---|---|---|---|---|
Anti-OX40/CD134 [OX86] |
Order |
Mouse IgG1 |
Agonism |
|
Anti-OX40/CD134 [OX86] | Order |
Mouse IgG2a | Agonism | |
Anti-PD-1 [RMP1-14] |
Order |
Mouse IgG2a Fc Silent™ |
Blocking |
|
Anti-CTLA-4 [9D9] |
Order |
Mouse IgG2a | Blocking, Treg depletion | |
Anti-CTLA-4 [9D9] | Order |
Mouse IgG2a Fc Silent™ | Blocking, peripheral Treg expansion | |
Anti-GITR [DTA-1] |
Order |
Mouse IgG2a |
Agonism |
|
Anti-CD25 [PC-61.5.3] |
Order |
Mouse IgG2a |
Depletion |
|
Anti-TIGIT [1B4] |
Order |
Mouse IgG1 |
Blocking |
|
Anti-Lag3 [C9B7W] | Order |
Mouse IgG2a Fc Silent™ | Blocking |
|
Anti-CD96 [6A6] |
Order |
Mouse IgG2a Fc Silent™ |
Blocking |
|
Anti-IL-10R [1B1.3a] |
Order |
Mouse IgG2a Fc Silent™ |
Blocking |
|
Anti-BTLA [HMBT-6B2] |
Order |
Mouse IgG2a Fc Silent™ |
Blocking | |
Anti-Tim-4 [3A1] |
Order |
Mouse IgG2a Fc Silent™ |
Blocking | |
Anti-Tim-4 [5G3] | Order |
Mouse IgG2a Fc Silent™ |
Blocking | |
Anti-TIM-2 [RMT2-14] | Order |
Mouse IgG2a Fc Silent™ |
Blocking | |
Anti-Tim-1 [3B3] | Order |
Mouse IgG1 | Agonism | |
Anti-Tim-3 [2C12] | Order |
Mouse IgG2a Fc Silent™ |
Blocking | |
Anti-CD115/M-CSFR [AFS98] | Order |
Mouse IgG2a | Depletion | |
Anti-PD-L1 [10F.9G2] | Order |
Mouse IgG2b |
Blocking | |
Anti-PD-L1 [10F.9G2] | Order |
Mouse IgG2b Fc Silent™ |
Blocking | |
Anti-IFN-gamma receptor 1 [GR20] | Order |
Mouse IgG2b Fc Silent™ |
Blocking | |
Anti-VISTA [13F3] | Order |
Mouse IgG2b Fc Silent™ |
Blocking | |
Anti-CD20 [18B12] | Order |
Mouse IgG2a | Depletion | |
Anti-CD4 epitope A [YTS 177.9] | Order |
Mouse IgG2a | Depletion | |
Anti-CD4 epitope A [YTS 191.1] | Order |
Mouse IgG2a | Depletion | |
Anti-CD8 alpha/Lyt-2 [YTS 169.4] | Order |
Mouse IgG2a | Depletion | |
Anti-Ly6G [1A8] | Order |
Mouse IgG2a | Depletion | |
Anti-CD200R [OX131] | Order |
Mouse IgG1 Fc Silent™ |
Blocking | |
Anti-PD-L2 [TY25] | Order |
Mouse IgG2a Fc Silent™ |
Blocking | |
Anti-Ly6G/Ly6C [RB6-8C5] | Order |
Mouse IgG2a | Depletion | |
Anti-Galectin 9 [RG9-35] | Order |
Mouse IgG2a Fc Silent™ | Blocking | |
Anti-CD153 [RM153] | Order |
Mouse IgG2a | Blocking | |
Anti-CD153 [RM153] | Order |
Mouse IgG2a Fc Silent™ | Blocking | |
Anti-CD155 [3F1] | Order |
Mouse IgG2a Fc Silent™ | Blocking | |
Anti-CD226 [10E5] | Order |
Mouse IgG2a Fc Silent™ | Blocking | |
Anti-CD45R [RA3-6B2] | Order |
Mouse IgG2a | Depletion | |
Anti-CD19 [6D5] | Order |
Mouse IgG2a | Depletion | |
Anti-HVEM [HMHV-1B18] | Order |
Mouse IgG2a Fc Silent™ | Blocking | |
Anti-CD27 [RM27-3E5] | Order |
Mouse IgG1 | Agonism | |
Anti-CD22 [OX-97] | Order |
Mouse IgG2a Fc Silent™ | Blocking | |
Anti-CD47 [mIAP301] | Order |
Mouse IgG2b Fc Silent™ | Blocking |
Recombinant F4/80 clone CI:A3-1
Uniquely available at Absolute Antibody!
Anti-F4/80 [Cl:A3-1] antibody is the most widely published and referenced mouse macrophage and microglia marker. At Absolute Antibody, they have sequenced the original hybridoma (Gordon and Austyn, 1981) and produced recombinant and chimeric anti-F4/80 clone Cl:A3-1 versions, allowing greater experimental flexibility and control for the end user!
Absoulte Antibody is the ONLY commercial manufacturer …
- … of recombinant F4/80 [Cl:A3-1] monoclonal antibody
- … of recombinant chimeric mouse anti-mouse F4/80 [CI:A3-1] monoclonal antibody
- … of recombinant rat anti-mouse and chimeric mouse anti-mouse F4/80 [CI:A3-1] antibodies with an effector-silent Fc domain (Fc Silent™).
Supporting Data for Anti-F4/80 [CI:A3-1 (recombinant version)]
In Figure 1 murine bone marrow-derived macrophages (BMDMs) were pre-blocked with rat anti-mouse CD16 & CD32 (clone FCR-4G8) and stained with non-recombinant anti-F4/80 [Cl:A3-1] conjugated to Alexa Fluor® 647 (AF647), all commercially available from competitors. In Figure 2 BMDMs were stained with recombinant anti-F4/80 [Cl:A3-1] or isotype control (anti-fluorescein [4-4-20 (enhanced)] IgG2b (Ab00102-8.1). In Figure 3 BMDMs were stained with Fc Silent™ recombinant anti-F4/80 [Cl:A3-1] (Ab00106-8.4) or isotype control (Fc Silent™ anti-fluorescein [4-4-20 (enhanced)] IgG2b (Ab00102-8.4). These were fluorescently labelled using the secondary antibody, goat IgG anti-rat IgG (H&L-chain) polyclonal antibody directly conjugated to Alexa Fluor® 647(AF647) commercially available from a competitor. Whilst in Figure 2 the highest fluorescence signal is seen with the recombinant anti-F4/80 IgG2 (the isotype of the original hybridoma-derived antibody), the isotype control IgG2b (Ab00102-8.1) shows considerable signal overlap, indicative of binding of the antibody to Fc-receptors. This illustrates the importance of isotype controls in such experiments when using conventional antibody formats particularly when Fc-blocking reagents are incompatible with the system used due to reactivity with the secondary antibody. The Fc silent™ format however overcomes this issue as seen in Figure 3, where the Fc silent™ recombinant anti-F4/80 (Ab00102-8.4) yields a strong and distinct signal, whilst the isotype control (Ab00102-8.4) shows no discernible difference to the background staining from the secondary antibody alone. Therefore, with Fc Silent™ reagents, no Fc-blocking products are required. [Data courtesy of Lewis Taylor.]